Inmed's inm-901 demonstrates statistically significant reduction in neuroinflammation in a long-term preclinical alzheimer's disease study

Inm-901 significantly reduced pro-inflammatory cytokines associated with alzheimer's statistically significant reduction in neurodegeneration marker, neurofilament light chain ('nfl') mrna profile showed a reduction of several key neuroinflammatory genes in the brain vancouver, british columbia--(newsfile corp. - january 21, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical alzheimer's disease ('ad') study. in the study, inm-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to alzheimer's disease development and progression.
INM Ratings Summary
INM Quant Ranking